Compare Amylx Pharmaceuticals Inc (AMLX) vs Best Buy Co Inc (BBY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Best Buy Co Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Best Buy Co Inc trades at $81.49 (market cap $17.45B). The key difference: Best Buy Co Inc is far larger — about 8.8× Amylx Pharmaceuticals Inc's market cap, and Best Buy Co Inc pays a 4.64% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | BBY | |
|---|---|---|
Market Cap | $1.98B | $17.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $18.70 | $84.00 |
52-Week Low | $7.64 | $55.52 |
Enterprise Value | $1.70B | $19.83B |
Dividend Yield | — | 4.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Best Buy (BBY) trades at $82.80, up 3.51% with a bullish technical signal. The stock shows strong profitability with a 39.1% ROE and has beaten earnings estimates for three consecutive quarters. Recent news highlights strategic shifts under new CEO Jason Bonfig toward higher-margin services like retail media and marketplace expansion, alongside new product launches such as RGB LED TVs and Meta VR partnerships.
Outlook remains cautiously optimistic with a consensus price target of $82.18. The attractive 4.6% dividend yield and improving cash flow support income investors, but risks include macroeconomic pressures on consumer electronics spending and leadership transitions. Revenue declines since 2022 require monitoring for stabilization under new growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →
